Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R-Mini-CYVE) regimen for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma not eligible for intensive chemotherapy.
Pamela AbdayemNathalie IbrahimYolla El DakdoukiChristophe WillekensDavid GhezJulia A RouchePeggy DartiguesRomain DesmarisAlina DanuJulien RossignolJulien LazaroviciChristophe FerméVincent RibragJean Marie MichotPublished in: European journal of haematology (2021)
R-mini-CYVE demonstrated a meaningful antitumour efficacy and an acceptable safety profile in patients with relapsed/refractory B-cell NHL who were ineligible for HDT.